Drugs and Devices

FDA announces new risk factor for PML associated with Tysabri

On Jan. 20, the U.S. Food and Drug Administration (FDA) announced that testing positive for anti-JC virus antibodies has been identified as a risk factor for progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection associated with use of Tysabri (natalizumab) for the treatment of multiple sclerosis or Crohn’s disease. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares